Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Knee Surgery In Second Attempt
This article was originally published in The Pink Sheet Daily
After failing to show non-inferiority in ADVANCE I, the Bristol/Pfizer anticoagulant was soundly superior to enoxaparin in ADVANCE II.
You may also be interested in...
Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half Along With New Application For Chronic Use
Chronic use application may help ease FDA's reluctance to make available a much anticipated and broadly applicable anticoagulant for the acute application in the original NDA.
Partnership with Pfizer cushions blow to Bristol-Myers’ new blood thinner.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.